Fyteko and Janssen PMP announce collaboration agreement for NURSPRAY^®

The agri-biomolecule developer Fyteko has announced a new collaboration agreement with Janssen PMP, a division of Janssen Pharmaceutica NV, for development of its novel crop biostimulant.

Fyteko and Janssen PMP have signed an Exclusive Agreement to evaluate the commercial potential of Nurspray^® in agricultural regions around the world where Janssen PMP has a solid footprint. Fyteko has granted Janssen PMP the right to use Nurspray^® intellectual property for evaluation and demonstration purposes. Under the agreement, Janssen PMP will perform field demonstrations and early market development activities necessary for commercialization. Fyteko continues to conduct field trials, R&D and regulatory development concurrently in other regions, collaborating with various companies.

NURSPRAY^® has been in development at Fyteko since 2014, when the company’s founders discovered hydroxycinnamic acid oligomers’ role as the crucial ‘signal’ molecule in plants’ natural defence mechanism against abiotic stress. Fyteko's sustainable solution has shown consistent efficacy in many regions and multiple crops, covering many environmental and soil conditions, over several years.

“Application of the biomolecule raises crop yields, but we also saw other improvements” says the company’s co-founder and CEO Guillaume Wegria, “field trials show impressive robustness and dispel any remaining concerns about the ability of bioproducts to stand their ground against conventional products,” he says.

“The strategic move to have such an innovative and effective biostimulant in our portfolio is a natural step forward for us” says Geoffroy de Chabot-Tramecourt, Head of R&D and Business Development at Janssen PMP. “Improving the quality and yield of fresh produce by applying technologies derived from nature is our priority”